FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167460557> ?p ?o ?g. }

• W3167460557 endingPage "e19035" @default.
• W3167460557 startingPage "e19035" @default.
• W3167460557 abstract "e19035 Background: Myelodysplastic syndromes (MDS) are clonal hemopoietic disorders causing cytopenia(s) and increased risk of transformation to acute myeloid leukemia (AML). Venetoclax is a B-cell lymphoma-2 (BCL-2) inhibitor that induces apoptosis in malignant cells. The FDA has approved venetoclax for the treatment of newly diagnosed adult AML patients unfit for intensive chemotherapy and its utility in MDS is being explored. We present a systematic review aimed to evaluate outcomes with venetoclax in MDS patients. Methods: We performed a literature search on 3 databases (Pubmed, Cochrane, and Clinicaltrials.gov) following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We screened 62 studies using the Mesh terms ‘myelodysplastic syndrome’ and ‘venetoclax’. After excluding review, duplicate and non-relevant articles, 8 studies were included in the analysis. Quality evaluation was done using the NIH quality assessment tool. Pooled analysis was done using the ‘meta’ package (Schwarzer et al, R programming language) and proportions with 95% confidence intervals (CI) were computed. The Inter-study heterogeneity among the studies was assessed using the Q statistic proposed by Cochrane and the I2 index introduced by Higgins and Thompson. Results: We identified 313 patients from 8 studies (1 prospective, 3 retrospective, 2 ex-vivo, 2 clinical trials). Venetoclax was used in combination with hypomethylating agents (HMA) in 6 studies and with other agents in 2 studies. Most patients were pre-treated. Complete response (CR) with or without hematological recovery (CRi) was reported in 45% of patients (95% CI 0.26-0.66, I 2 = 90%, n = 292). Stable disease (SD) was seen in 18% patients (95% CI 0.08-0.37, I 2 = 85%, n = 223). Overall response rate (ORR) was 51% (95% CI 0.31-0.70, I 2 = 89%, n = 122). Hematopoietic stem cell transplant (HCT) was performed in 22% patients (95% CI 0.09-0.44, I 2 = 75%, n = 122). Twenty percent patients (95% CI 0.15-0.28, I 2 = 0%, n = 149) died. Common adverse events seen with venetoclax were cytopenias, gastrointestinal side effects and infections, often requiring drug interruption or dose. Conclusions: Despite heterogeneity of available literature, venetoclax seems to be a promising agent in treatment of MDS patients. Prospective clinical trial data is needed to ascertain safety and efficacy of venetoclax in MDS and impact on overall survival, in particular, in patients proceeding to HCT.[Table: see text]" @default.
• W3167460557 created "2021-06-22" @default.
• W3167460557 creator A5000881706 @default.
• W3167460557 creator A5005991606 @default.
• W3167460557 creator A5007547408 @default.
• W3167460557 creator A5008400959 @default.
• W3167460557 creator A5020301952 @default.
• W3167460557 creator A5028841827 @default.
• W3167460557 creator A5033591617 @default.
• W3167460557 creator A5038186608 @default.
• W3167460557 creator A5041882264 @default.
• W3167460557 creator A5052064208 @default.
• W3167460557 creator A5062279447 @default.
• W3167460557 creator A5068826793 @default.
• W3167460557 creator A5086587597 @default.
• W3167460557 creator A5088949367 @default.
• W3167460557 creator A5089584574 @default.
• W3167460557 creator A5091688355 @default.
• W3167460557 date "2021-05-20" @default.
• W3167460557 modified "2023-09-24" @default.
• W3167460557 title "Outcomes with venetoclax in myelodysplastic syndromes: A systematic review." @default.
• W3167460557 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e19035" @default.
• W3167460557 hasPublicationYear "2021" @default.
• W3167460557 type Work @default.
• W3167460557 sameAs 3167460557 @default.
• W3167460557 citedByCount "0" @default.
• W3167460557 crossrefType "journal-article" @default.
• W3167460557 hasAuthorship W3167460557A5000881706 @default.
• W3167460557 hasAuthorship W3167460557A5005991606 @default.
• W3167460557 hasAuthorship W3167460557A5007547408 @default.
• W3167460557 hasAuthorship W3167460557A5008400959 @default.
• W3167460557 hasAuthorship W3167460557A5020301952 @default.
• W3167460557 hasAuthorship W3167460557A5028841827 @default.
• W3167460557 hasAuthorship W3167460557A5033591617 @default.
• W3167460557 hasAuthorship W3167460557A5038186608 @default.
• W3167460557 hasAuthorship W3167460557A5041882264 @default.
• W3167460557 hasAuthorship W3167460557A5052064208 @default.
• W3167460557 hasAuthorship W3167460557A5062279447 @default.
• W3167460557 hasAuthorship W3167460557A5068826793 @default.
• W3167460557 hasAuthorship W3167460557A5086587597 @default.
• W3167460557 hasAuthorship W3167460557A5088949367 @default.
• W3167460557 hasAuthorship W3167460557A5089584574 @default.
• W3167460557 hasAuthorship W3167460557A5091688355 @default.
• W3167460557 hasConcept C126322002 @default.
• W3167460557 hasConcept C143998085 @default.
• W3167460557 hasConcept C2777938653 @default.
• W3167460557 hasConcept C2778461978 @default.
• W3167460557 hasConcept C2778729363 @default.
• W3167460557 hasConcept C2779675984 @default.
• W3167460557 hasConcept C2780007613 @default.
• W3167460557 hasConcept C2780366003 @default.
• W3167460557 hasConcept C2780817109 @default.
• W3167460557 hasConcept C71924100 @default.
• W3167460557 hasConceptScore W3167460557C126322002 @default.
• W3167460557 hasConceptScore W3167460557C143998085 @default.
• W3167460557 hasConceptScore W3167460557C2777938653 @default.
• W3167460557 hasConceptScore W3167460557C2778461978 @default.
• W3167460557 hasConceptScore W3167460557C2778729363 @default.
• W3167460557 hasConceptScore W3167460557C2779675984 @default.
• W3167460557 hasConceptScore W3167460557C2780007613 @default.
• W3167460557 hasConceptScore W3167460557C2780366003 @default.
• W3167460557 hasConceptScore W3167460557C2780817109 @default.
• W3167460557 hasConceptScore W3167460557C71924100 @default.
• W3167460557 hasIssue "15_suppl" @default.
• W3167460557 hasLocation W31674605571 @default.
• W3167460557 hasOpenAccess W3167460557 @default.
• W3167460557 hasPrimaryLocation W31674605571 @default.
• W3167460557 hasRelatedWork W10110336 @default.
• W3167460557 hasRelatedWork W1133061 @default.
• W3167460557 hasRelatedWork W12916179 @default.
• W3167460557 hasRelatedWork W2918413 @default.
• W3167460557 hasRelatedWork W5027048 @default.
• W3167460557 hasRelatedWork W5342291 @default.
• W3167460557 hasRelatedWork W6398642 @default.
• W3167460557 hasRelatedWork W8604413 @default.
• W3167460557 hasRelatedWork W893036 @default.
• W3167460557 hasRelatedWork W17826350 @default.
• W3167460557 hasVolume "39" @default.
• W3167460557 isParatext "false" @default.
• W3167460557 isRetracted "false" @default.
• W3167460557 magId "3167460557" @default.
• W3167460557 workType "article" @default.